23 March 2016 | Press releases

Video: A partnership to revolutionize MDR-TB treatments around the world

Tuberculosis (TB) has now overtaken HIV as the deadliest infection worldwide, and we’re also losing ground to drug-resistant TB. Worse still: treatments for ‘multidrug-resistant tuberculosis’ (MDR-TB) are long, ineffective and have terrible side effects, including acute psychosis and permanent deafness.

After 50 years without new TB drugs, two were developed recently: bedaquiline and delamanid.

We’re partnering with leading medical organizations to get these drugs to patients in 15 countries, and revolutionise MDR-TB treatments. It’s called endTB.

View All News

Featured News

12 July 2024

Call for Expression of Interest (EOI): Strengthening sustainable regional manufacturing of therapeutics for Maternal health, Malaria and HIV programmatic priorities in Africa

Read More

09 July 2024

Unitaid and Jhpiego reach first women with prevention and treatment for life-threatening bleeding as program awarded EUR 5.5 million in additional funding

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.